Artur Aymar is sure he wants to study Biomedical Engineering; for this reason, he is happy to perform the research work in one of the VHIR’s laboratories as it is the opportunity to learn first-hand “what kind of research takes place in a real...
Read moreDr. Simó Schwartz Jr has been appointed as a member of the advisory board of the EU-NCL
Dr. Simó Schwartz Jr, director of the CIBBIM-Nanomedicine of the Vall d’Hebron Institute of Research (VHIR), has been appointed as a member of the advisory board of the Nanomedicine Characterisation Laboratory (EU-NCL). Dr. Schwartz will...
Read moreLa Masia and the AECC promoting a solidarity oil for breast cancer research
The Spanish Association Against Cancer (AECC) and La Masía have presented today the initiative «Aceite de Oliva Solidario» (Solidarity Olive Oil). The goal of the challenge – which starts today and ends on October 19, World Day Against Breast...
Read moreDr. Simó Schwartz, Scientific, appointed president of the European Society for Nanomedicine (ESNAM)
The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in...
Read moreDr. Schwartz Jr participates in a European nanomedicine project for pancreatic cancer
The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, called NoCanTher, which aims to develop treatments with nanomedicine for pancreatic ductal...
Read moreDr Simó Schwartz Jr is appointed editor of the European Journal of Nanomedicine
Dr Simó Schwartz Jr, director of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), has been appointed member of the editorial board of the European Journal of Nanomedicine. VHIR’s researcher will review some of the...
Read moreThree VHIR researchers receive three important European grants
Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of...
Read moreNew methodology to improve the drug response of breast and colon cancer with nanomedicine
Researchers from the Drug Delivery and Targeting group of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VIHR), have evidenced that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. To be...
Read moreVHIR researchers presented the results funded by the Marató of 2009 devoted to rare diseases
On Monday afternoon, 20 research projects funded by La Marató 2009 devoted to rare diseases were presented in the 16th Symposium La Marató of TV3, at the Institut d’Estudis Catalans’ facilities. There were researchers from Vall d’Hebron, who had...
Read morePossible new strategies to combat epithelial metastatic cancer have been described
An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d’Hebron Research Institute...
Read more